{"disease":{"id":"p53-mutations","name":"p53 mutations"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01443468","title":"Clinical and Genetic Studies of Li-Fraumeni Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06088030","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Yang Li","has_results":false},{"nct_id":"NCT04695223","title":"Arsenic Trioxide for Structural p53 Mutations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}